We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Research Partners Seek Antibodies for Cancer Therapy

By Biotechdaily staff writers
Posted on 25 Dec 2007
The discovery, development, and commercialization of novel therapeutic antibodies for the treatment of cancer are the objectives of new strategic research collaboration.

Oxford Genome Sciences (Oxford, UK) and Amgen (Thousand Oaks, CA, USA) plan to generate fully human antibodies using Amgen's proprietary XenoMouse technology. More...
These antibodies will be raised against the novel druggable targets that Oxford Genome Sciences has identified through its Oxford Genome Anatomy Project (OGAP) database.

OGAP maintains a database comprising what has been described as the world's largest proprietary collection of proteins. It integrates genomic, proteomics, and clinical information derived from blood and tissue studies for a large number of diseases from 50 different human tissues and representing 60 diseases. It contains over one million peptide sequences, mapped to approximately 15,000 genes, and over eight million SNPs and haplotypes. The OGAP oncology section contains proteomic data on 5,000 cancer membrane proteins combined with their genomic and clinical information derived from human blood and cancer tissue studies.

Dr Christian Rohlff, CEO of Oxford Genome Sciences said, "I am very happy to be collaborating with Amgen in our effort to discover and develop novel fully human antibodies for the treatment of cancer. I am confident that by using our complementary expertise we will be able to develop a promising and valuable pipeline of antibodies.”

Dr. Dave Lacey, head of research at Amgen, said, "We are pleased to enter into this collaboration that takes advantage of Amgen's expertise in monoclonal antibody technology and the database that Oxford Genome Sciences has established.”


Related Links:
Oxford Genome Sciences
Amgen

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image: At the MHH Institute of Human Genetics: Prof. Dr. Doris Steinemann, Dr. Bernardus Aldrige Allister and Prof. Dr Monika Golas (from left). (Image Credit: Karin Kaiser/MHH)

Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer

Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.